Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...
Dr Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brandDr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and ...
Dr Reddy’s shares slip nearly 2% on investor concerns amid $50 million foray into anti-vertigo categoryDr. Reddy's Laboratories' shares experienced a slight dip following the announcement of their acquisition of Stugeron from Johnson & Johnso...